Applied Therapeutics Inc
NASDAQ:APLT
Applied Therapeutics Inc
Cash from Operating Activities
Applied Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Applied Therapeutics Inc
NASDAQ:APLT
|
Cash from Operating Activities
-$94m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$16.4B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$10.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$12.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
-$980.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
|
Applied Therapeutics Inc
Glance View
Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
See Also
What is Applied Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-94m
USD
Based on the financial report for Mar 31, 2025, Applied Therapeutics Inc's Cash from Operating Activities amounts to -94m USD.
What is Applied Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-14%
Over the last year, the Cash from Operating Activities growth was -40%.
You don't have any saved screeners yet